Perfil clínico de pacientes con inmunodeficiencia secundaria en terapia sustitutiva con inmunoglobulina.

Saved in:

Bibliographic Details
Title:	Perfil clínico de pacientes con inmunodeficiencia secundaria en terapia sustitutiva con inmunoglobulina.
Alternate Title:	Clinical profile of patients with secondary immunodeficiency on immunoglobulin replacement therapy.
Authors:	Méndez-Gómez, Alicia¹, Gómez-Hernández, Noemí¹, Ortega-Cisneros, Margarita¹, Gutiérrez-Zepeda, Bricia Melissa², de Jesús Quintero-Rodríguez, Antonio³, Duran-Marín, Luis Alberto¹, Rosaldo-Solís, Marya Lizzeth¹, Quintero-Ramos, Antonio⁴
Source:	Revista Medica del IMSS. 2026 Supplement, Vol. 64, p1-6. 6p.
Subjects:	IMMUNODEFICIENCY, CORTICOSTEROIDS, INFECTION, RHEUMATOLOGY, RITUXIMAB, BLOOD diseases, IMMUNOSUPPRESSIVE agents, SEROTHERAPY
Abstract (English):	Background: Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment. Objective: To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT). Material and methods: A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed. Results: The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%. Conclusions: The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases. [ABSTRACT FROM AUTHOR]
Abstract (Spanish):	Introducción: la inmunodeficiencia secundaria (SID) es un trastorno en el que el sistema inmunológico se ve comprometido por factores externos o adquiridos, reduciendo la cantidad o la función de las inmunoglobulinas. Esta condición incrementa la necesidad de interconsulta, seguimiento y terapia sustitutiva, lo que a su vez eleva los costos en salud. A la fecha, existen pocos estudios que caractericen clínicamente a los pacientes con SID; por ello, conocer su perfil permitirá un mejor abordaje y tratamiento. Objetivo: describir el perfil clínico de pacientes con SID que reciben terapia sustitutiva con inmunoglobulina humana (IgG-RT). Material y métodos: se realizó un estudio observacional retrospectivo mediante la revisión de 40 expedientes clínicos de pacientes con SID en tratamiento con IgG-RT. Se analizaron factores de riesgo y los beneficios de la terapia sustitutiva. Resultados: la edad promedio fue de 48 años, con predominio de mujeres (62.5%). Las patologías más frecuentes fueron las reumatológicas (38%), seguidas de las hematológicas (31%) y las enfermedades perdedoras de proteínas (27%). Todos los pacientes habían recibido corticoesteroides en combinación con otro inmunosupresor, y el 77.5% también había sido tratado con rituximab. Se registraron infecciones en el 50% de los casos; sin embargo, solo el 35% recibió profilaxis. Se documentó recaída en el 22.5% de los pacientes y una mortalidad del 2.5%. Conclusiones: el uso de corticoesteroides e inmunosupresores, específicamente rituximab, constituyó la principal causa de SID, asociada predominantemente a enfermedades reumatológicas y hematológicas. [ABSTRACT FROM AUTHOR]
	Copyright of Revista Medica del IMSS is the property of Direccion de Prestaciones Medicas - IMSS and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database:	MedicLatina

Description
Abstract:	Background: Secondary immunodeficiency (SID) is a disorder in which the immune system is compromised by external or acquired factors, reducing the quantity or function of immunoglobulins. This condition increases the need for specialist consultation, follow-up, and replacement therapy, which in turn raises healthcare costs. To date, few studies have clinically characterized patients with SID; therefore, understanding their profile will enable improved management and treatment. Objective: To describe the clinical profile of patients with SID receiving human immunoglobulin replacement therapy (IgG-RT). Material and methods: A retrospective observational study was conducted through the review of 40 medical records of patients with SID undergoing IgG-RT. Risk factors and the benefits of replacement therapy were analyzed. Results: The mean age was 48 years, with a predominance of women (62.5%). The most frequent conditions were rheumatologic diseases (38%), followed by hematologic disorders (31%) and protein-losing diseases (27%). All patients had received corticosteroids in combination with another immunosuppressant, and 77.5% had also been treated with rituximab. Infections were recorded in 50% of cases; however, only 35% received prophylaxis. Relapse was documented in 22.5% of patients, and mortality was 2.5%. Conclusions: The use of corticosteroids and immunosuppressants, specifically rituximab, was the main cause of SID, predominantly associated with rheumatologic and hematologic diseases. [ABSTRACT FROM AUTHOR]
ISSN:	04435117
DOI:	10.5281/zenodo.19099403